CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $6.01B, above the global median of $1.2B
- PositionProfit margin is 67.9%, higher than 95% of its Biotechnology peers (median -57.5%)
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.01BUSDvs all stocks (USD)
Trailing P/E
31.02xvs Biotechnology peers
Revenue (TTM)
290.54MUSDvs all stocks (USD)
Profit Margin
67.88%vs Biotechnology peers
Beta
0.9760xvs all stocks
52-Week Change
74.16%vs all stocks
Market Capitalization
6.01BUSDvs all stocks (USD)
Enterprise Value
5.78BUSDvs all stocks (USD)
Trailing P/E
31.02xvs Biotechnology peers
Forward P/E
25.26xvs Biotechnology peers
PEG Ratio
0.0357xvs Biotechnology peers
Price to Sales (TTM)
20.69xvs Biotechnology peers
Price to Book (MRQ)
6.21xvs Biotechnology peers
Enterprise to Revenue
19.91xvs Biotechnology peers
Enterprise to EBITDA
43.49xvs Biotechnology peers
Gross Margin
94.95%vs Biotechnology peers
Profit Margin
67.88%vs Biotechnology peers
Operating Margin
13.49%vs Biotechnology peers
Return on Assets (TTM)
3.99%vs Biotechnology peers
Return on Equity (TTM)
21.96%vs Biotechnology peers
Revenue (TTM)
290.54MUSDvs all stocks (USD)
Revenue per Share (TTM)
14.75USDUpdated Sep 27, 2026Quarterly Revenue Growth
33.70%vs Biotechnology peers
Gross Profit (TTM)
235.92MUSDvs all stocks (USD)
EBITDA (TTM)
94.54MUSDvs all stocks (USD)
Net Income (TTM)
197.22MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
900.80%vs Biotechnology peers
Operating Cash Flow (TTM)
131.71MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
139.75MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
268.09MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
14.55MUSDFY2025 · Dec 31, 2025Gross Profit
253.54MUSDFY2025 · Dec 31, 2025Operating Income
47.20MUSDvs all stocks (USD)
Pre-tax Income
158.96MUSDFY2025 · Dec 31, 2025Income Tax Expense
34.51MUSDFY2025 · Dec 31, 2025Net Income
124.45MUSDFY2025 · Dec 31, 2025EBIT
163.68MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
94.54MUSDFY2025 · Dec 31, 2025Research & Development
81.18MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
92.45MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.66MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
4.71MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
124.45MUSDFY2025 · Dec 31, 2025Operating Cash Flow
214.06MUSDFY2025 · Dec 31, 2025Free Cash Flow
213.60MUSDDerived from operating cash flow minus capital expenditure. This filing charges 33.78M of depreciation against 452K of capital expenditure, and its own free-cash-flow line reads 38.05M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
174.93MUSDFY2025 · Dec 31, 2025Income Tax Paid
7.80MUSDFY2025 · Dec 31, 2025Interest Paid
321.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
124.45MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
33.77MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
22.68MUSDFY2025 · Dec 31, 2025Stock-based Compensation
46.85MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.84MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-21.74MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
3.19MUSDFY2025 · Dec 31, 2025Capital Expenditures
-452.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-601.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
-8.39MUSDFY2025 · Dec 31, 2025Purchase of Investments
-740.50MUSDFY2025 · Dec 31, 2025Sale of Investments
377.28MUSDFY2025 · Dec 31, 2025Other Investing Activity
-4.66MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-376.72MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
466.91MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-113.28MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-15.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-25.30MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
313.33MUSDFY2025 · Dec 31, 2025Shares Outstanding
19.92MSharesUpdated Sep 27, 2026Float Shares
19.48MSharesUpdated Sep 27, 2026Shares Short
2.63MSharesUpdated Sep 27, 2026Short Ratio
14.08daysvs all stocks
Short % of Shares Outstanding
15.83%vs all stocks
% Held by Insiders
2.35%vs all stocks
% Held by Institutions
116.03%vs all stocks
Total Cash (MRQ)
1.36BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
68.11USDUpdated Sep 27, 2026Total Debt (MRQ)
1.13BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.17xvs Biotechnology peers
Current Ratio (MRQ)
31.18xvs Biotechnology peers
Book Value per Share (MRQ)
48.57USDUpdated Sep 27, 2026Total Assets
1.56BUSDvs all stocks (USD)
Total Current Assets
832.27MUSDFY2025 · Dec 31, 2025Total Liabilities
543.42MUSDFY2025 · Dec 31, 2025Total Non-current Assets
728.37MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
505.98MUSDFY2025 · Dec 31, 2025Total Current Liabilities
37.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
174.93MUSDFY2025 · Dec 31, 2025Other Short-term Investments
581.39MUSDFY2025 · Dec 31, 2025Accounts Receivable
59.60MUSDFY2025 · Dec 31, 2025Inventory
9.13MUSDFY2025 · Dec 31, 2025Accounts Payable
3.24MUSDFY2025 · Dec 31, 2025Short-term Debt
1.09MUSDFY2025 · Dec 31, 2025Deferred Revenue
621.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
422.00KUSDFY2025 · Dec 31, 2025Long-term Debt
450.40MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
19.56MUSDFY2025 · Dec 31, 2025Common Stock (Book)
20.00KUSDFY2025 · Dec 31, 2025Retained Earnings
608.09MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.02BUSDvs all stocks (USD)
52-Week Low
166.10USDUpdated Sep 27, 202652-Week High
326.63USDUpdated Sep 27, 202652-Week Change
74.16%vs all stocks
Beta
0.9760xvs all stocks
50-Day MA
291.07USDUpdated Sep 27, 2026200-Day MA
238.72USDUpdated Sep 27, 2026Avg 10-Day Volume
256.29KSharesUpdated Sep 27, 2026Avg 30-Day Volume
211.60KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
9.72USDUpdated Sep 27, 2026Other Income / Expense
102.82MUSDFY2025 · Dec 31, 20257 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Debt Financing Activity
More cash moved through borrowing and repaying than through the business itself, and most of its debt is long-term.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Diagnostic
High ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Return on equity reads high, with a large gap between pretax and operating income.
Reads
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 67.9%, higher than 95% of its Biotechnology peers (median -57.5%)Significant
Profit margin: 0.68Industry median: -0.58Industry P95: 0.37Peers compared: 258
Return on equity is 22%, higher than 95% of its Biotechnology peers (median -23.3%)Significant
Return on equity: 0.22Industry median: -0.23Industry P95: 0.19Peers compared: 258
Current ratio is 31.18×, higher than 95% of its Biotechnology peers (median 5.96×)Significant
Current ratio: 31.18Industry median: 5.96Industry P95: 22.30Peers compared: 258
Debt-to-equity is 1.17×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 1.17Industry median: 0.07Industry P95: 0.86Peers compared: 258
Financial Health
Altman Z-Score 8.31: safe zoneNotable
Altman Z-Score: 8.31
High structural barrier to entryNotable
Barrier to Entry: 0.56
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $6.01B, above the global median of $1.2BNotable
Market cap (USD): 6,010,984,626Global Median: 1,201,862,193
Levered free cash flow is $139.75M, above the global median of $18.92MNotable
Levered free cash flow (USD): 139,748,880Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Anthem Biosciences Limited
Tier 1ProductionApproval-Gated PipelineFlowSenseMaking
GenScript Biotech Corporation
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Duality Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Relay Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Irhythm Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Globus Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bio-Techne Corporation
Tier 1ProductionApproval-Gated PipelineFlowInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Holystar Electric Co., Ltd.
6 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-DecelerationLow-Leverage Liquidity ConfigurationCash Backing With OCF Coverage And Cash Near Total Debt
Shanghai Shuixing Home Textile Co., Ltd.
5 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity ConfigurationCash Backing With OCF Coverage And Cash Near Total Debt
Beijing Tricolor Technology Co., Ltd.
5 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-DecelerationLow-Leverage Liquidity Configuration